Suppr超能文献

1型纤溶酶原激活物抑制剂(PAI-1)与肝素的功能相互作用

Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin.

作者信息

Ehrlich H J, Keijer J, Preissner K T, Gebbink R K, Pannekoek H

机构信息

Department of Molecular Biology, Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, Amsterdam.

出版信息

Biochemistry. 1991 Jan 29;30(4):1021-8. doi: 10.1021/bi00218a020.

Abstract

Plasminogen activator inhibitor type 1 (PAI-1), the fast-acting inhibitor of tissue-type plasminogen activator (t-PA) and urokinase (u-PA), is a member of the serpin superfamily of proteins. Both in plasma and in the growth substratum of cultured endothelial cells, PAI-1 is associated with its binding protein vitronectin, resulting in a stabilization of active PAI-1. Recently, it has been demonstrated that the PAI-1-binding site on vitronectin is adjacent to a heparin-binding site (Preissner et al., 1990). Furthermore, it can be deduced that the amino acid residues, proposed to mediate heparin binding in the serpins antithrombin III and heparin cofactor II, are conserved in PAI-1. Consequently, here we have investigated whether PAI-1 also interacts with heparin. At pH 7.4, PAI-1 quantitatively binds to heparin-Sepharose and can be eluted with increasing [NaCl]. Binding of PAI-1 to heparin-Sepharose can be efficiently competed with heparin in solution (IC50, 7 microM). In the presence of heparin, the protease specificity of PAI-1 toward thrombin is substantially increased. This is shown by (i) quenching of thrombin activity of PAI-1 in the presence of heparin and (ii) induction of the formation of SDS-stable complexes between thrombin and PAI-1 by heparin. In a dose response curve, both effects reached a maximum at approximately 1 unit/mL and then diminished again upon further increasing the heparin concentration, strongly suggesting a template mechanism as an explanation for the observed effect. In contrast to vitronectin, heparin does not stabilize the active conformation of PAI-1.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

1型纤溶酶原激活物抑制剂(PAI-1)是组织型纤溶酶原激活物(t-PA)和尿激酶(u-PA)的快速作用抑制剂,属于丝氨酸蛋白酶抑制剂超家族成员。在血浆和培养的内皮细胞生长基质中,PAI-1均与其结合蛋白玻连蛋白相关联,从而使活性PAI-1得以稳定。最近有研究表明,玻连蛋白上的PAI-1结合位点与肝素结合位点相邻(Preissner等人,1990年)。此外,可以推断,在丝氨酸蛋白酶抑制剂抗凝血酶III和肝素辅因子II中被认为介导肝素结合的氨基酸残基在PAI-1中是保守的。因此,我们在此研究了PAI-1是否也与肝素相互作用。在pH 7.4时,PAI-1可定量结合至肝素琼脂糖,并且可以通过增加[NaCl]浓度进行洗脱。PAI-1与肝素琼脂糖的结合可被溶液中的肝素有效竞争(IC50为7 microM)。在肝素存在下,PAI-1对凝血酶的蛋白酶特异性显著增加。这表现为:(i)在肝素存在下PAI-1对凝血酶活性的淬灭;(ii)肝素诱导凝血酶与PAI-1之间形成SDS稳定复合物。在剂量反应曲线中,两种效应在约1单位/mL时达到最大值,然后在进一步增加肝素浓度时再次减弱,强烈表明模板机制可解释观察到的效应。与玻连蛋白不同,肝素不会稳定PAI-1的活性构象。(摘要截短至250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验